Anti-CD20 monoclonal antibody that depletes B cells to modulate humoral immune responses.
Anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B cells and depletes them via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis, thereby suppressing humoral immune responses.
Rituximab binds CD20 on B cells and elicits killing via Fc-mediated ADCC (e.g., NK cells/macrophages), complement-dependent cytotoxicity (MAC formation), and can induce apoptosis upon CD20 cross-linking.
Biosimilar to rituximab; anti-CD20 monoclonal antibody that depletes B cells.
Biosimilar to rituximab; a chimeric anti‑CD20 monoclonal antibody that binds CD20 on pre‑B and mature B cells and depletes them primarily via antibody‑dependent cellular cytotoxicity and complement‑dependent cytotoxicity, with additional direct apoptotic signaling, thereby reducing B‑cell–mediated immune responses.
Anti-CD20 antibody binds CD20 on B cells and induces killing via Fc-mediated ADCC (engaging NK cells/macrophages) and complement-dependent cytotoxicity, with additional direct apoptotic signaling upon CD20 cross-linking.
Autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy (relma-cel, JWCAR029) in which a patient’s T cells are engineered to express a CD19-directed CAR (CD3ζ with costimulation) to induce cytotoxicity and cytokine release against CD19+ B cells; used for B-cell malignancies.
Autologous T cells are genetically engineered to express a CD19-directed chimeric antigen receptor (including CD3ζ signaling and costimulatory domains). Upon binding CD19 on malignant B cells, CAR activation triggers T‑cell cytotoxicity and cytokine release, selectively eliminating CD19+ cells and often causing B‑cell aplasia.
Anti‑CD19 CAR T cells bind CD19 on target cells, activating T‑cell cytotoxicity (perforin/granzyme release and Fas–FasL signaling) to induce apoptosis of CD19+ cells.
Humanized anti-HER2 monoclonal antibody that inhibits HER2 signaling and mediates antibody-dependent cellular cytotoxicity (ADCC).
Humanized IgG1 monoclonal antibody that binds HER2 (ERBB2), inhibits HER2 signaling and receptor activation/dimerization, and recruits immune effector cells via Fc-mediated ADCC to kill HER2-overexpressing tumor cells.
Binds HER2 on tumor cells and engages FcγR-bearing immune cells (e.g., NK cells) to trigger antibody-dependent cellular cytotoxicity, killing HER2+ cells; also may activate complement and inhibit HER2 signaling.
Humanized anti-HER2 monoclonal antibody that blocks HER2 dimerization and downstream signaling.
Humanized monoclonal antibody targeting the HER2 dimerization domain (subdomain II), preventing HER2 hetero-/homodimerization (notably with HER3) and downstream PI3K/AKT and MAPK signaling, leading to growth inhibition and apoptosis; also engages Fc-mediated ADCC.
Pertuzumab binds HER2 and both blocks HER2 dimerization/signaling (triggering growth inhibition and apoptosis) and engages immune effectors via its Fc to mediate ADCC against HER2-expressing cells.